Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | VRK2 | Q86Y07 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615838 | 0.85 | MAP4K4 (0.51) | MAP4K4FYNMAPTUSP7CHEK2 | |
| SCHEMBL2556015 | 0.84 | CHEK2 (0.52) | MAP4K4FYNMAPTCHEK2PDGFRB | |
| SCHEMBL14276837 | 0.83 | MAP4K4 (0.49) | MAP4K4FYNMAPTUSP7CHEK2 | |
| SCHEMBL29955261 | 0.83 | MAP4K4 (0.49) | MAP4K4FYNMAPTUSP7CHEK2 | |
| SCHEMBL2560884 | 0.83 | MAP4K4 (0.54) | MAP4K4USP7 | |
| SCHEMBL29954696 | 0.81 | ERN1 (0.51) | MAP4K4FYNERN1CHEK2PDGFRB | |
| SCHEMBL5126305 | 0.80 | MAP4K4 (0.54) | MAP4K4FYNALDH1A1CHRNA7ERN1 | |
| SCHEMBL2557668 | 0.79 | CA12 (0.47) | MAP4K4 | |
| SCHEMBL124004 | 0.78 | ERN1 (0.39) | MAP4K4ALDH1A1ERN1CHEK2 | |
| SCHEMBL31056338 | 0.78 | ERN1 (0.39) | MAP4K4ALDH1A1ERN1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-7329678-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329678-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329678-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1590339-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060148854-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1590339-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069160-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069160-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148854-A1 | Chemical compounds | SGK1, SGK2, SGK3 | MAP4K4 31/4885FYN 787/4885HDAC1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.